Eloxx Pharmaceuticals (ELOX) vs Elutia (ELUT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Eloxx Pharmaceuticals is the larger company by market cap ($43.7 million vs $40.0 million), about 1.1 times the size, while Elutia is growing revenue faster (-15.0% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELOX | ELUT |
|---|---|---|
| Share price | $10.69 | $0.9001 |
| Market cap | $43.69M | $39.96M |
| 1-day change | -1.75% | +11.12% |
| YTD return | — | +29.88% |
| 1-year return | — | +52.56% |
| 5-year return | — | -82.76% |
| P/E ratio (TTM) | 5.63 | — |
| EPS (TTM) | $1.90 | $-0.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $12.29M |
| Revenue growth (YoY) | -100.00% | -15.03% |
| Net income (latest FY) | $-6.00M | $53.38M |
| Gross margin | — | 53.66% |
| Operating margin | — | -218.91% |
| Net margin | — | 434.23% |
| 52-week high | $23.40 | $1.39 |
| 52-week low | $8.20 | $0.50 |
| Distance from 52-week high | -54.32% | -35.01% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +257.81% | +455.49% |
| Average volume | 28.48K | 185.17K |
| Shares outstanding | 4.09M | 44.40M |
| Employees | 10 | 25 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Elutia grew revenue faster in its latest fiscal year (-15.03% vs -100.00%).
About Eloxx Pharmaceuticals
ELOX stock →Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 10 employees
About Elutia
ELUT stock →Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 25 employees
ELOX vs ELUT FAQ
Which is bigger, Eloxx Pharmaceuticals or Elutia?
Eloxx Pharmaceuticals (ELOX) is larger, with a market capitalization of $43.69M compared with $39.96M for Elutia (ELUT).
Are Eloxx Pharmaceuticals and Elutia in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.